17-alpha-hydroxyprogesterone has been researched along with urea in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
Chaube, SK; Kariya, KP; Kumar, D; Prasad, PK; Shrivastav, TG | 1 |
Auchus, RJ; Chang, AY; El-Maouche, D; Joyal, EG; Lin, VH; Merke, DP; Mohideen, P; Plaunt, MR; Turcu, AF; Vogiatzi, MG; Weintraub, L | 1 |
Speiser, PW | 1 |
1 trial(s) available for 17-alpha-hydroxyprogesterone and urea
Article | Year |
---|---|
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Oral; Adolescent; Adrenal Cortex; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adult; Androstenedione; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucocorticoids; Humans; Middle Aged; Treatment Outcome; Urea; Young Adult | 2020 |
3 other study(ies) available for 17-alpha-hydroxyprogesterone and urea
Article | Year |
---|---|
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Influence of different length spacers containing enzyme conjugate on functional parameters of progesterone ELISA.
Topics: 17-alpha-Hydroxyprogesterone; Adipates; Aminocaproic Acid; Animals; Antigens; Enzyme-Linked Immunosorbent Assay; Ethylenediamines; Horseradish Peroxidase; Immunoglobulin G; Progesterone; Rabbits; Serum Albumin, Bovine; Urea | 2013 |
Invited Commentary: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Humans; Urea | 2020 |